A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients

por Kowalski, Mark, Entwistle, Joycelyn, Cizeau, Jeannick, Niforos, Demi, Loewen, Shauna, Chapman, Wendy, MacDonald, Glen C
Publicado 2010

DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents

por Chooniedass, Shilpa, Dillon, Rachelle L., Premsukh, Arjune, Hudson, Peter J., Adams, Gregory P., MacDonald, Glen C., Cizeau, Jeannick
Publicado 2016

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

por MacDonald, Glen C, Rasamoelisolo, Michèle, Entwistle, Joycelyn, Cizeau, Jeannick, Bosc, Denis, Cuthbert, Wendy, Kowalski, Mark, Spearman, Maureen, Glover, Nick
Publicado 2009